.png){kind=icon}
.png){kind=icon}
Return
Evaluating safety: Number needed to harm analyses of androgen receptor inhibitors in advanced prostate cancer
.png){kind=icon}
PRE
AI
D
K
A
H
Y
S
M
A
F
DOI：10.1016/j.ejca.2026.116982.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• NNH analyses compared ARI safety profiles in nmCRPC and mHSPC • Darolutamide had a more favorable NNH for most AEs vs other ARIs • Favorable NNH trends applied to both all-grade and grade ≥3 AEs • Darolutamide maintained a lower incremental harm risk over time in nmCRPC • NNH results may help guide patient-centered ARI selection in prostate cancer
Journal
IF:
7.1
Papers:
2.6W
Citations:
3.8W
View more organizations